



## Prof. Dr. André Schrattenholz

Organisation	ProteoSys AG
Department	
Position	Chief Science Officer
Location/Country	Germany
E-mail address	Andre.schrattenholz@proteosys.com
Website	<a href="http://www.proteosys.com">www.proteosys.com</a>
Short biography (max 300 words)	<p>André Schrattenholz is co-founder and Chief Science Officer of ProteoSys AG, a German research company focussed on systems biology and proteomics. He is a lecturing professor at the Institute of Pathophysiology and Pathobiochemistry of the Medical Faculty of the University of Mainz.</p> <p>After studies of biology and chemistry at the University of Mainz, Germany and the University of California in San Diego and Berkeley, he became group leader and lecturer in molecular neurobiology at the University of Mainz.</p> <p>Since the foundation of ProteoSys in 2000, participation in a variety of publically funded research projects, BMBF and many within European projects (FP5-FP7); Numerous publications and conference contributions (see <a href="http://www.proteosys.com">www.proteosys.com</a>);</p>

## Selected publications

Groebe K, Hayess K, Klemm-Manns M, Steemans M, Peters A, Schwall G, Wozny W, Sastri S, Jaeckel P, Stegmann W, Zengerling H, Schöpf R, Poznanovic S, Stumman T, Seiler A, Spielmann H, **Schrattenholz A** (2010) Protein biomarkers for in vitro testing of embryotoxicity, **J. Proteome Res., in press**

Shakib K, **Schrattenholz A**, Šoškić V (2010) Stem Cells in Head and Neck Squamous Cell Carcinoma. **British Journal Oral Maxillofacial Surgeons, in press**

Groebe K, Hayess K, Klemm-Manns M, Steemans M, Peters A, Schwall G, Wozny W, Sastri S, Jaeckel P, Stegmann W, Zengerling H, Schöpf R, Poznanovic S, Stumman T, Seiler A, Spielmann H, **Schrattenholz A** (2010) Unexpected common mechanistic pathways for embryotoxicity of warfarin and lovastatin. **Reproductive Toxicology 30(1), 121-130.**

Groebe K, Klemm-Manns M, Schwall GP, Hübenthal H, Unterluggauer H, Janssen-Dürr P, Tanguay R, Morrow, G and **Schrattenholz A** (2010) Age-dependent posttranslational modifications of voltage-dependent anion channel 1 and the role of the mitochondrial transition pore. **Exper. Gerontology 45 (7-8), 632-637.**

**Schrattenholz A**, Šoškić V and Groebe K (2010) Synchronisation of posttranslational modifications during ageing: time is a crucial biological dimension. **Ann. NY Acad. Sci. 1197, 118-28.**

**Schrattenholz A**, Groebe K and Šoškić V (2010) Systems Biology Approaches and Tools for Analysis of Interactomes and Multi-Target Drugs, **Methods in Molecular Biology 662, 29-58**

Riss P, Šoškić V, **Schrattenholz A** and Rösch F (2009) Synthesis and radiosynthesis of N5-[18F]fluoroethyl-Pirenzepine and its metabolite N5-[18F]fluoroethyl-LS 75. **Journal of Labelled Compounds and Radiopharmaceuticals, in press**

Kuegler PB, Zimmer B, Waldmann T, Baudis B, Ilmjärv S, Hescheler J, Gaughwin P, Brundin P, Mundy W, Bal-Price AK, **Schrattenholz A**, Krause K-H, van Thriel C, Rao MS, Kadereit S and Leist M (2010) Markers of murine embryonic and neural stem cells, neurons and astrocytes: reference points for developmental neurotoxicity testing – a review by the Transatlantic Think Tank for Toxicology (t<sup>4</sup>) **ALTEX. 27:16-42.**

Henn A, Lund S, Hedtjärn M, **Schrattenholz A**, Pörzgen P, Leist M. (2009) The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. **ALTEX. 26(2):83-94.**

Schostak M, Schwall GP, Poznanović S, Groebe K, Müller M, Messinger D, Miller K, Krause H, Pelzer A, Horninger W, Klocker H, Hennenlotter J, Feyerabend S, Stenzl A, **Schrattenholz A** (2009) Non-invasive diagnosis of prostate cancer by annexin A3 quantification from urine is superior to serum PSA. **Journal of Urology, 181(1):343-53.**

**Schrattenholz A** and Šoškić V (2008) What does systems biology mean for drug development? **Current Medicinal Chemistry**, **15(15)**, 1520-1528

Köllermann J, Bang H, Schwall GP, von Eichel-Streiber C, Simon R, Schlomm T, Huland H, Berg W, Sauter G, Klocker H and **Schrattenholz A** (2008) Expression and Prognostic Relevance of Annexin A3 in Prostate Cancer, **European Urology**, **54(6)**:1314-1323.

**Schrattenholz A** and Groebe K (2007) What does it need to be a biomarker? Relationships between resolution, differential quantification and statistical validation of protein surrogate biomarkers. **Electrophoresis**, **28(12)**, 1970-1979.

**Schrattenholz A** and Šoškić V (2006) NMDA receptors are not alone: Dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling **Current Topics in Medicinal Chemistry**, **6(7)**, 663-686.